Bausch + Lomb Co. (NYSE:BLCO) Receives $20.91 Consensus PT from Analysts

Bausch + Lomb Co. (NYSE:BLCO) has been given an average rating of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.91.

A number of research firms recently commented on BLCO. Royal Bank of Canada lifted their price target on Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft raised their price objective on Bausch + Lomb from $14.00 to $18.00 and gave the stock a “hold” rating in a research note on Thursday, August 1st. Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. Evercore lifted their price target on shares of Bausch + Lomb from $15.50 to $17.00 and gave the company an “in-line” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Company boosted their price objective on shares of Bausch + Lomb from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Gabelli Funds LLC lifted its stake in Bausch + Lomb by 3.3% during the first quarter. Gabelli Funds LLC now owns 312,000 shares of the company’s stock valued at $5,398,000 after purchasing an additional 10,000 shares during the last quarter. Whitebox Advisors LLC raised its position in shares of Bausch + Lomb by 29.3% during the first quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company’s stock worth $20,869,000 after purchasing an additional 273,484 shares during the period. Invenomic Capital Management LP purchased a new stake in shares of Bausch + Lomb during the first quarter valued at $6,817,000. Rokos Capital Management LLP acquired a new position in shares of Bausch + Lomb in the 1st quarter valued at $5,602,000. Finally, Renaissance Capital LLC raised its holdings in Bausch + Lomb by 57.2% during the 2nd quarter. Renaissance Capital LLC now owns 36,286 shares of the company’s stock worth $527,000 after buying an additional 13,210 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 0.4 %

Shares of Bausch + Lomb stock opened at $19.76 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The business has a 50-day moving average of $19.43 and a 200-day moving average of $16.90. The company has a market capitalization of $6.96 billion, a PE ratio of -18.82, a P/E/G ratio of 1.92 and a beta of 0.46.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm earned $0.22 earnings per share. The business’s revenue was up 18.8% compared to the same quarter last year. As a group, equities analysts forecast that Bausch + Lomb will post 0.59 EPS for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.